Patient Activity Decreases and Mortality Increases After the Onset of Persistent Atrial Fibrillation in Patients With Implantable Cardioverter-Defibrillators.
The study sought to determine the effect of persistent atrial fibrillation (AF) on device-measured activity and mortality. Patients with AF often complain of fatigue, which may be reflected in patient activity. Daily activity can be objectively measured by implanted devices. We retrospectively studied patients (n = 266, 88% male, 69 ± 10 years of age) from the deidentified Medtronic CareLink database with persistent AF (≥28 consecutive days with ≥23 h of AF/day), dual-chamber implantable cardioverter-defibrillators (ICDs) capable of monitoring daily activity and AF burden, no AF between months 1 and 6 post-implant, and ≥1 year of data. The first persistent AF episode occurred 980 ± 534 days after implant and lasted a median of 87 days (interquartile range: 49 to 161 days). Average daily activity over a week just prior (baseline) to the first persistent AF episode was compared to each of the 4 weeks during the AF episode and to each of the weeks following termination of the persistent AF episode. Daily activity decreased significantly from the baseline week (135 min/day) compared to each of the 4 consecutive weeks after AF onset (8%, 11%, 14%, and 17% decrease, p < 0.001). Mortality at 4 years was increased in patients with persistent AF compared to a matched group with no persistent AF (20.6% vs. 8.6%, p < 0.01). Patients with ICDs have a significant reduction in activity following the onset of persistent AF and a significant increase in mortality when compared to a matched group without persistent AF. Objective measures of activity may more accurately reflect the impact of persistent AF on patients' functional status.